MENU
+Compare
INMB
Stock ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$4.58
Change
-$0.40 (-8.03%)
Capitalization
110.42M

INMB INmune Bio Forecast, Technical & Fundamental Analysis

a developer of therapies that harness the patient's immune system to treat cancer

Industry Biotechnology
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for INMB with price predictions
Dec 17, 2024

INMB's RSI Indicator climbs out of oversold territory

The RSI Indicator for INMB moved out of oversold territory on November 21, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In of the 32 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for INMB just turned positive on December 03, 2024. Looking at past instances where INMB's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where INMB advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

INMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on INMB as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

INMB moved below its 50-day moving average on December 11, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for INMB crossed bearishly below the 50-day moving average on November 21, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INMB entered a downward trend on December 02, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. INMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.626) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). INMB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). INMB's P/S Ratio (2000.000) is slightly higher than the industry average of (260.687).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

INMB is expected to report earnings to fall 8.15% to -55 cents per share on February 27

INmune Bio INMB Stock Earnings Reports
Q4'24
Est.
$-0.55
Q3'24
Missed
by $0.08
Q2'24
Beat
by $0.13
Q1'24
Missed
by $0.08
Q4'23
Missed
by $0.04
The last earnings report on October 31 showed earnings per share of -60 cents, missing the estimate of -51 cents. With 269.59K shares outstanding, the current market capitalization sits at 110.42M.
A.I. Advisor
published General Information

General Information

a developer of therapies that harness the patient's immune system to treat cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 NE Mizner Boulevard
Phone
+1 858 964-3720
Employees
17
Web
https://www.inmunebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EMPYF0.260.02
+7.96%
Empress Royalty Corp.
MGDDY16.880.01
+0.06%
CIE GENERALE DES ETABLISSEMENTS MICHELIN SA CLERMONT-FERRAND
GLNCY9.14-0.11
-1.19%
Glencore Plc
ZLNDY17.73-0.24
-1.34%
ZALANDO SE
ZPTAF3.69-0.05
-1.34%
Surge Energy, Inc.

INMB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with MDGL. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
-1.97%
MDGL - INMB
41%
Loosely correlated
-1.58%
ORMP - INMB
38%
Loosely correlated
-1.67%
AXON - INMB
37%
Loosely correlated
-2.09%
PRME - INMB
34%
Loosely correlated
-3.00%
CYTK - INMB
34%
Loosely correlated
-2.53%
More